Thermo Fisher Scientific Expands Rapid Equilibrium Dialysis Line for Drug Discovery Research
The newest RED Devices are specifically designed and extensively validated for plasma serum-binding assays. The devices can also be used for determining drug partition between red blood cells and plasma, protein binding of liver microsomes to improve the correlation between in vitro and in vivo intrinsic clearance and the competition between tissue protein binding against plasma proteins. The Single-Use RED Plate is validated for minimal nonspecific binding.
The RED Devices accommodate sample sizes between 100-500 microliters. The high membrane surface-to-volume ratios of the devices enable rapid dialysis, reaching equilibrium in less than four hours with high levels of reproducibility and accuracy. The plate format requires no extensive assembly steps or specialized equipment, and each chamber is easily accessible from the top of the device.
For more information on the new Single-Use RED Device products, please visit www.thermoscientific.com/pierce.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.